Peptides and proteins are widely used to treat a range of medical conditions; however, they often have to be injected and their effects are short-lived. These shortcomings of the native structure can be addressed by molecular engineering, but this is a complex undertaking. A molecular engineering technology initially applied to insulin — and which has now been successfully applied to several biopharmaceuticals — entails the derivatization of peptides and proteins with fatty acids. Various protraction mechanisms are enabled by the specific characteristics and positions of the attached fatty acid. Furthermore, the technology can ensure a long half-life following oral administration of peptide drugs, can alter the distribution of peptides and may hold potential for tissue targeting. Due to the inherent safety and well-defined chemical nature of the fatty acids, this technology provides a versatile approach to peptide and protein drug discovery.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Muttenthaler, M., King, G. F., Adams, D. J. & Alewood, P. F. Trends in peptide drug discovery. Nat. Rev. Drug Discov. 20, 309–325 (2021). This Review focuses on the current and future aspects of peptide drug discovery.
Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug Discov. 21, 201–223 (2022). This Review provides a perspective on the challenges of targeting obesity, particularly with novel peptide-based concepts.
Strohl, W. R. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29, 215–239 (2015).
Evans, M. et al. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review. Diabetes Obes. Metab. 24, 377–390 (2022).
Polonsky, W. H., Fisher, L., Hessler, D., Bruhn, D. & Best, J. H. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes. Metab. 13, 144–149 (2011).
Hashimoto, M., Takada, K., Kiso, Y. & Muranishi, S. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm. Res. 6, 171–176 (1989).
Kurtzhals, P. et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand–protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312, 725–731 (1995). This work is the first demonstration of an extended half-life by albumin binding of fatty acid-derivatized peptides.
Hannoush, R. N. Synthetic protein lipidation. Curr. Opin. Chem. Biol. 28, 39–46 (2015).
Mejuch, T. & Waldmann, H. Synthesis of lipidated proteins. Bioconjug. Chem. 27, 1771–1783 (2016).
Chen, B., Sun, Y., Niu, J., Jarugumilli, G. K. & Wu, X. Protein lipidation in cell signaling and diseases: function, regulation, and therapeutic opportunities. Cell Chem. Biol. 25, 817–831 (2018).
Richter, W. F., Bhansali, S. G. & Morris, M. E. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 14, 559–570 (2012).
Gradel, A. K. J. et al. Factors affecting the absorption of subcutaneously administered insulin: effect on variability. J. Diabetes Res. 2018, 1205121 (2018).
Hildebrandt, P., Sejrsen, P., Nielsen, S. L., Birch, K. & Sestoft, L. Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. Scand. J. Clin. Lab. Invest. 45, 685–690 (1985).
Mosekilde, E., Jensen, K. S., Binder, C., Pramming, S. & Thorsteinsson, B. Modeling absorption kinetics of subcutaneous injected soluble insulin. J. Pharmacokinet. Biopharm. 17, 67–87 (1989).
Kuna, M., Mahdi, F., Chade, A. R. & Bidwell, G. L. III Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Sci. Rep. 8, 7923 (2018).
Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539–551 (2001).
Peters, T. Jr. Serum albumin. Adv. Protein Chem. 37, 161–245 (1985).
Ellmerer, M. et al. Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am. J. Physiol. Endocrinol. Metab. 278, E352–E356 (2000).
Nilsen, J. et al. An intact C-terminal end of albumin is required for its long half-life in humans. Commun. Biol. 3, 181 (2020).
Chaudhury, C. et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197, 315–322 (2003).
Ober, R. J., Martinez, C., Lai, X., Zhou, J. & Ward, E. S. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc. Natl Acad. Sci. USA 101, 11076 (2004).
He, X. M. & Carter, D. C. Atomic structure and chemistry of human serum albumin. Nature 358, 209–215 (1992).
Curry, S., Mandelkow, H., Brick, P. & Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 5, 827–835 (1998). This work presents the structural basis for fatty acid binding to serum albumin.
Irby, D., Du, C. & Li, F. Lipid–drug conjugate for enhancing drug delivery. Mol. Pharm. 14, 1325–1338 (2017).
Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145–160 (2005).
Bhat, M., Jatyan, R., Mittal, A., Mahato, R. I. & Chitkara, D. Opportunities and challenges of fatty acid conjugated therapeutics. Chem. Phys. Lipids 236, 105053 (2021).
Smith, R. & Tanford, C. Hydrophobicity of long chain n-alkyl carboxylic acids, as measured by their distribution between heptane and aqueous solutions. Proc. Natl Acad. Sci. USA 70, 289 (1973).
Spector, A. A. Fatty acid binding to plasma albumin. J. Lipid Res. 16, 165–179 (1975).
Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58, 7370–7380 (2015). This work is the first demonstration of the once-weekly potential of applying the fatty acid derivatization technology.
Østergaard, S. et al. The effect of fatty diacid acylation of human PYY3–36 on Y2 receptor potency and half-life in minipigs. Sci. Rep. 11, 21179 (2021). This paper demonstrates the importance of fatty acid position, linker and backbone stability in engineering PYY analogues with long half-lives.
Enseñat-Waser, R. et al. Direct visualization by confocal fluorescent microscopy of the permeation of myristoylated peptides through the cell membrane. IUBMB Life 54, 33–36 (2002).
Nelson, A. R., Borland, L., Allbritton, N. L. & Sims, C. E. Myristoyl-based transport of peptides into living cells. Biochemistry 46, 14771–14781 (2007).
Kabanov, A. V., Levashov, A. V. & Alakhov, V. Y. Lipid modification of proteins and their membrane transport. Protein Eng. Des. Sel. 3, 39–42 (1989).
Gao, X., Mazière, A. D., Beard, R., Klumperman, J. & Hannoush, R. N. Fatty acylation enhances the cellular internalization and cytosolic distribution of a cystine-knot peptide. iScience 24, 103220 (2021).
Bech, E. M. et al. Half-life extending modifications of peptide YY3–36 direct receptor-mediated internalization. Mol. Pharm. 16, 3665–3677 (2019).
Mäde, V., Bellmann-Sickert, K., Kaiser, A., Meiler, J. & Beck-Sickinger, A. G. Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues. ChemMedChem 9, 2463–2474 (2014).
Alexopoulou, F. et al. Lipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect. Sci. Rep. 12, 1696 (2022). This methodological study highlights the differences between monoacid and diacid side chains.
Poulsen, C. et al. Rational development of stable PYY3–36 peptide Y2 receptor agonists. Pharm. Res. 38, 1369–1385 (2021).
Conde-Frieboes, K. et al. Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. J. Med. Chem. 55, 1969–1977 (2012).
Ramírez-Andersen, H. S. et al. Long-acting human growth hormone analogue by noncovalent albumin binding. Bioconjug. Chem. 29, 3129–3143 (2018).
Ostergaard, S. et al. Selective PYY compounds and uses thereof. US Patent US2015/0152150 A1 (2015).
Madsen, K. et al. Structure−activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. 50, 6126–6132 (2007).
Wieczorek, B., Spetzler, J. C., Kruse, T., Linderoth, L. & Kofoed, J. Double-acylated GLP-1 derivatives. US Patent WO2012/140117 (2012).
Yang, P.-Y. et al. Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery. Proc. Natl Acad. Sci. USA 113, 4140–4145 (2016).
Royalty, J. E., Konradsen, G., Eskerod, O., Wulff, B. S. & Hansen, B. S. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects. J. Clin. Pharmacol. 54, 394–404 (2014).
Lau, J., F., Kruse, T., Linderoth, L. & Thøgersen, H. Novel glucagon analogues. US Patent WO2011/117416 Al (2011).
Ward, B. P. et al. Peptide lipidation stabilizes structure to enhance biological function. Mol. Metab. 2, 468–479 (2013). This work demonstrates the role that the fatty acid side chain plays in determining the structural stability and receptor binding of peptide drugs.
Coskun, T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol. Metab. 18, 3–14 (2018). This work presents the design of the first once-weekly fatty acid-derivatized GLP-1/GIP co-agonist to enter the clinic.
Kjeldsen, T. B. et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J. Med. Chem. 64, 8942–8950 (2021). This work presents the design of the first once-weekly insulin based on fatty acid derivatization.
van Witteloostuijn, S. B. et al. Neoglycolipids for prolonging the effects of peptides: self-assembling glucagon-like peptide 1 analogues with albumin binding properties and potent in vivo efficacy. Mol. Pharm. 14, 193–205 (2017).
Zorzi, A., Middendorp, S. J., Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Nat. Commun. 8, 16092 (2017).
Johansson, E. et al. Identification of binding sites on human serum albumin for somapacitan, a long-acting growth hormone derivative. Biochemistry 59, 1410–1419 (2020).
Yáñez, J. A., Remsberg, C. M., Sayre, C. L., Forrest, M. L. & Davies, N. M. Flip-flop pharmacokinetics — delivering a reversal of disposition: challenges and opportunities during drug development. Ther. Deliv. 2, 643–672 (2011).
Markussen, J. et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39, 281–288 (1996).
Myers, S. R. et al. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 46, 637–642 (1997).
Radziuk, J. et al. Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Diabetologia 41, 116–120 (1998).
Nicol, D. S. & Smith, L. F. Amino-acid sequence of human insulin. Nature 187, 483–485 (1960).
Potocka, E., Baughman, R. A. & Derendorf, H. Population pharmacokinetic model of human insulin following different routes of administration. J. Clin. Pharmacol. 51, 1015–1024 (2011).
Smith, L. F. Species variation in the amino acid sequence of insulin. Am. J. Med. 40, 662–666 (1966).
Havelund, S., Halstrom, J., Jonassen, I. K. P. & Markussen, J. Characterization of B1 and B29 fatty acid acylated insulins. Diabetologia 38, A192 (1995).
Havelund, S. et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21, 1498–1504 (2004).
Heinemann, L. et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet. Med. 16, 332–338 (1999).
Brunner, G. A. et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp. Clin. Endocrinol. Diabetes 108, 100–105 (2000).
Heller, S. et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379, 1489–1497 (2012).
Garber, A. J. et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379, 1498–1507 (2012).
Hermansen, K. et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29, 1269–1274 (2006).
Vague, P. et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26, 590–596 (2003).
Jonassen, I. et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104–2114 (2012).
Steensgaard, D. B. et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry 52, 295–309 (2013).
Haahr, H. & Heise, T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin. Pharmacokinet. 53, 787–800 (2014).
Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11–22 (2015). This work is the first pivotal study that demonstrates the weight loss potential in humans by a fatty acid-derivatized GLP-1 analogue.
Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016). This work presents the first demonstration of the cardiovascular benefits of a fatty acid-derivatized GLP-1 analogue.
Kreymann, B., Ghatei, M. A., Williams, G. & Bloom, S. R. Glucagon-like peptide1 7–36: a physiological incretin in man. Lancet 330, 1300–1304 (1987).
Nathan, D. M., Schreiber, E., Fogel, H., Mojsov, S. & Habener, J. F. Insulinotropic action of glucagonlike peptide-I-(7–37) in diabetic and nondiabetic subjects. Diabetes Care 15, 270 (1992).
Nauck, M. A. et al. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301–307 (1993).
Deacon, C. F., Johnsen, A. H. & Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952–957 (1995).
Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664–1669 (2000). This work presents the first once-daily GLP-1 analogue designed by fatty acid derivatization.
Steensgaard, D. B., Thomsen, J. K., Olsen, H. B. & Knudsen, L. B. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes 57, A164 (2008).
Wang, Y., Lomakin, A., Kanai, S., Alex, R. & Benedek, G. B. Transformation of oligomers of lipidated peptide induced by change in pH. Mol. Pharm. 12, 411–419 (2015).
Wang, Y. et al. The molecular basis for the prolonged blood circulation of lipidated incretin peptides: peptide oligomerization or binding to serum albumin. J. Control. Rel. 241, 25–33 (2016).
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P. & Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45, 195–202 (2002).
Elbrønd, B. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25, 1398–1404 (2002).
Garber, A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473–481 (2009).
Buse, J. B. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47 (2009).
Sonne, O. Receptor-mediated endocytosis and degradation of insulin. Physiol. Rev. 68, 1129–1196 (1988).
Ward, C. W., Menting, J. G. & Lawrence, M. C. The insulin receptor changes conformation in unforeseen ways on ligand binding: sharpening the picture of insulin receptor activation. Bioessays 35, 945–954 (2013).
Menting, J. G. et al. How insulin engages its primary binding site on the insulin receptor. Nature 493, 241–245 (2013).
Ribel, U., Hougaard, P., Drejer, K. & Sørensen, A. R. Equivalent in vivo biological activity of insulin analogues and human insulin despite different in vitro potencies. Diabetes 39, 1033–1039 (1990).
Ellmerer, M. et al. Mechanism of action in dogs of slow-acting insulin analog O346. J. Clin. Endocrinol. Metab. 88, 2256–2262 (2003).
Hubálek, F. et al. Molecular engineering of safe and efficacious oral basal insulin. Nat. Commun. 11, 3746 (2020). This work presents insights into the development of oral insulin by applying fatty acid derivatization.
Nakagawa, S. H. & Tager, H. S. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects. J. Biol. Chem. 261, 7332–7341 (1986).
Halberg, I. B. et al. The effect of food intake on the pharmacokinetics of oral basal insulin: a randomised crossover trial in healthy male subjects. Clin. Pharmacokinet. 58, 1497–1504 (2019).
Kjeldsen, T. B. et al. Engineering of orally available, ultralong-acting insulin analogues: discovery of OI338 and OI320. J. Med. Chem. 64, 616–628 (2021).
Halberg, I. B. et al. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol. 7, 179–188 (2019).
Hamilton-Wessler, M. et al. Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion. Diabetes 51, 574–582 (2002).
Ludvigsen, S., Olsen, H. B. & Kaarsholm, N. C. A structural switch in a mutant insulin exposes key residues for receptor binding. J. Mol. Biol. 279, 1–7 (1998).
Ludvigsen, S., Roy, M., Thøgersen, H. & Kaarsholm, N. C. High-resolution structure of an engineered biologically potent insulin monomer, B16 Tyr → His, as determined by nuclear magnetic resonance spectroscopy. Biochemistry 33, 7998–8006 (1994).
Nishimura, E. et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res. Care 9, e002301 (2021).
Rosenstock, J. et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N. Engl. J. Med. 383, 2107–2116 (2020).
Mendez Perez, M. et al. Insulin conjugates. WO2020120463 (2020).
Brennan, S. P., Flora, D. B., Kisselev, V., Liu, W. & Valenzuela, F. A. Extended time action acylated insulin compounds. WO2021231676 (2021).
Sorli, C. et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 5, 251–260 (2017).
Aroda, V. R. et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 5, 355–366 (2017).
Marso, S. P., Holst, A. G. & Vilsbøll, T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 376, 891–892 (2017). This key study demonstrates the cardiovascular benefits of the once-weekly fatty acid-derivatized GLP-1 analogue semaglutide.
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989 (2021).
Gallo, M. et al. Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: an investigation on lipidated GLP-1 analogs. J. Pharm. Biomed. Anal. 210, 114566 (2022).
Staby, A. et al. Influence of production process and scale on quality of polypeptide drugs: a case study on GLP-1 analogs. Pharm. Res. 37, 120 (2020).
Zapadka, K. L., Becher, F. J., Gomes Dos Santos, A. L. & Jackson, S. E. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 7, 20170030 (2017).
Pedersen, J. S. The nature of amyloid-like glucagon fibrils. J. Diabetes Sci. Technol. 4, 1357–1367 (2010).
Abraham, M. A. et al. GIP/GLP-1 co-agonist compounds. US Patent 2020/0024322 A1 (2020).
Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 143–155 (2021). This work presents the efficacy of a fatty acid-derivatized once-weekly GLP-1/GIP co-agonist in type 2 diabetes.
Frías, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503–515 (2021).
Del Prato, S. et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398, 1811–1824 (2021).
Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2206038 (2022). This work is the first pivotal study to demonstrate weight-lowering potential of a fatty acid-derivatized GLP-1/GIP dual receptor agonist.
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G. & Roth, J. D. Amylin: pharmacology, physiology, and clinical potential. Pharmacol. Rev. 67, 564–600 (2015).
Kapurniotu, A. Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. Pept. Sci. 60, 438–459 (2001).
Younk, L. M., Mikeladze, M. & Davis, S. N. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert. Opin. Pharmacother. 12, 1439–1451 (2011).
Kruse, T. et al. Development of cagrilintide, a long-acting amylin analogue. J. Med. Chem. 64, 11183–11194 (2021). This work presents the design of a once-weekly amylin analogue by fatty acid derivatization.
Hansen, K. T., Schaffer, L. & Lau, J. Amylin derivatives. US Patent 2009/0099085 (2009).
Reidelberger, R. D., Arnelo, U., Granqvist, L. & Permert, J. Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R605–R611 (2001).
Enebo, L. B. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397, 1736–1748 (2021).
Lau, D. C. W. et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398, 2160–2172 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03600480 (2022).
Batterham, R. L. et al. Gut hormone PYY3–36 physiologically inhibits food intake. Nature 418, 650–654 (2002).
Hutchinson, J. A. et al. The effect of lipidation on the self-assembly of the gut-derived peptide hormone PYY3–36. Bioconjug. Chem. 29, 2296–2308 (2018).
Dich, J. & Nielsen, K. Metabolism and distribution of I-labelled albumin in the pig. Can. J. Comp. Med. Vet. Sci. 27, 269–273 (1963).
de Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306–312 (1992).
Press, M. Growth hormone and metabolism. Diabetes Metab. Rev. 4, 391–414 (1988).
Helleberg, H., Lindecrona, R. H., Thygesen, P. & Bjelke, M. Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats. Eur. J. Pharm. Sci. 168, 106032 (2021).
Johannsson, G. et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J. Clin. Endocrinol. Metab. 105, e1358–e1376 (2020).
Rasmussen, M. H., Olsen, M. W., Alifrangis, L., Klim, S. & Suntum, M. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile. J. Clin. Endocrinol. Metab. 99, E1819–E1829 (2014).
Howard, J. F. et al. RA101495, a subcutaneously administered peptide inhibitor of complement component 5 (C5) for the treatment of generalized myasthenia gravis (gMG): phase 1 results and phase 2 design (S31.006). Neurology 90, S31.006 (2018).
Howard, J. F. Jr. et al. Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis. Expert. Opin. Invest. Drugs 30, 483–493 (2021).
Ekrami, H. M., Kennedy, A. R. & Shen, W.-C. Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. FEBS Lett. 371, 283–286 (1995).
Honeycutt, L., Wang, J., Ekrami, H. & Shen, W. C. Comparison of pharmacokinetic parameters of a polypeptide, the Bowman–Birk protease inhibitor (BBI), and its palmitic acid conjugate. Pharm. Res. 13, 1373–1377 (1996).
Dasgupta, P., Singh, A. T. & Mukherjee, R. Lipophilization of somatostatin analog RC-160 improves its bioactivity and stability. Pharm. Res. 16, 1047–1053 (1999).
Wang, J., Shen, D. & Shen, W.-C. Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity. Pharm. Res. 16, 1674–1679 (1999).
Wan, L., Chen, Y.-H. & Chang, T. W. Improving pharmacokinetic properties of adrenocorticotropin by site-specific lipid modification. J. Pharm. Sci. 92, 1882–1892 (2003).
Wang, J., Chow, D., Heiati, H. & Shen, W.-C. Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Rel. 88, 369–380 (2003).
Yuan, L., Wang, J. & Shen, W.-C. Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. Pharm. Res. 22, 220–227 (2005).
Bellmann-Sickert, K. et al. Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation. J. Med. Chem. 54, 2658–2667 (2011).
Lee, J. et al. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia. Int. J. Pharm. 424, 50–57 (2012).
Chae, S. Y. et al. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J. Control. Release 144, 10–16 (2010).
Lim, S. I. et al. Site-specific fatty acid-conjugation to prolong protein half-life in vivo. J. Control. Release 170, 219–225 (2013).
Dalbøge, L. S. et al. Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake. J. Pept. Sci. 21, 85–94 (2015).
Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27–36 (2015). This work presents engineering of once-weekly GLP-1/GIP/glucagon receptor tri-agonists by fatty acid derivatization.
Nissen, K. B., Andersen, J. J., Haugaard-Kedström, L. M., Bach, A. & Strømgaard, K. Design, synthesis, and characterization of fatty acid derivatives of a dimeric peptide-based postsynaptic density-95 (PSD-95) inhibitor. J. Med. Chem. 58, 1575–1580 (2015).
Trier, S. et al. Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement. Eur. J. Pharm. Biopharm. 96, 329–337 (2015).
Maletínská, L. et al. Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration. Int. J. Obes. 39, 986–993 (2015).
Chong, H., Wu, X., Su, Y. & He, Y. Development of poteny and long-acting HIV-1 fusion inhibitors. AIDS 30, 1187–1196 (2016).
Juhl, C. et al. Development of potent and metabolically stable APJ ligands with high therapeutic potential. ChemMedChem 11, 2378–2384 (2016).
Tanday, N., Irwin, N., Moffett, R. C., Flatt, P. R. & O’Harte, F. P. M. Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation. Diabetes Obes. Metab. 22, 2468–2478 (2020).
Naik, H., Gauthier, T., Singh, S. & Jois, S. Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2+ cancer. Bioorg. Med. Chem. Lett. 28, 3506–3513 (2018).
Williams, E. T. et al. Solid-phase thiol–ene lipidation of peptides for the synthesis of a potent CGRP receptor antagonist. Angew. Chem. Int. Ed. 57, 11640–11643 (2018).
Muppidi, A. et al. Design and synthesis of potent, long-acting lipidated relaxin-2 analogs. Bioconjug. Chem. 30, 83–89 (2019).
Sensfuss, U. et al. Structure–activity relationships and characterization of highly selective, long-acting, peptide-based cholecystokinin 1 receptor agonists. J. Med. Chem. 62, 1407–1419 (2019).
Christoffersen, B. et al. Long-acting CCK analogue NN9056 lowers food intake and body weight in obese Göttingen minipigs. Int. J. Obes. 44, 447–456 (2020).
Lay, Y. H., Andrade, P. D., Wu, Y. & Spring, D. R. Peptide stapling techniques based on different macrocyclisation chemistries. Chem. Soc. Rev. 44, 91–102 (2015).
Pflimlin, E. et al. Design of a long-acting and selective MEG–fatty acid stapled prolactin-releasing peptide analog. ACS Med. Chem. Lett. 10, 1166–1172 (2019).
Lear, S. et al. Engineering of a potent, long-acting NPY2R agonist for combination with a GLP-1R agonist as a multi-hormonal treatment for obesity. J. Med. Chem. 63, 9660–9671 (2020).
Farmer, T. D. et al. Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp. Am. J. Physiol. Endocrinol. Metab. 308, E206–E222 (2015).
Edgerton, D. S., Moore, M. C., Gregory, J. M., Kraft, G. & Cherrington, A. D. Importance of the route of insulin delivery to its control of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 320, E891–E897 (2021).
Gregory, J. M. et al. Peripherally delivered hepatopreferential insulin analog insulin-406 mimics the hypoglycaemia-sparing effect of portal vein human insulin infusion in dogs. Diabetes Obes. Metab. 21, 2294–2304 (2019).
Kurtzhals, P. et al. Commemorating insulin’s centennial: engineering insulin pharmacology towards physiology. Trends Pharmacol. Sci. 42, 620–639 (2021).
Pratley, R. et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 394, 39–50 (2019). This pivotal study demonstrates the efficacy of an oral peptide drug, semaglutide, versus subcutaneous liraglutide for the treatment of type 2 diabetes.
Gabery, S. et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5, e133429 (2020).
Asada, H. et al. Stability of acyl derivatives of insulin in the small intestine: relative importance of insulin association characteristics in aqueous solution. Pharm. Res. 11, 1115–1120 (1994).
Meier, J. J. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front. Endocrinol. 12, 645617 (2021).
Davies, M. et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318, 1460–1470 (2017).
Buckley, S. T. et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci. Transl. Med. 10, eaar7047 (2018).
Trier, S., Linderoth, L., Bjerregaard, S., Andresen, T. L. & Rahbek, U. L. Acylation of glucagon-like peptide-2: interaction with lipid membranes and in vitro intestinal permeability. PLoS ONE 9, e109939 (2014).
Rocco, D., Ross, J., Murray, P. E. & Caccetta, R. Acyl lipidation of a peptide: effects on activity and epidermal permeability in vitro. Drug Des. Devel. Ther. 10, 2203–2209 (2016).
Jensen, L. et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur. J. Pharm. Sci. 104, 31–41 (2017).
Malm-Erjefält, M. et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab. Dispos. 38, 1944–1953 (2010).
Kurtzhals, P., Havelund, S., Jonassen, I. & Markussen, J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J. Pharm. Sci. 86, 1365–1368 (1997).
Hausner, H. et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clin. Pharmacokinet. 56, 1391–1401 (2017).
Jordy, A. B. et al. Effect of oral semaglutide on the pharmacokinetics of levonorgestrel and ethinylestradiol in healthy postmenopausal women and furosemide and rosuvastatin in healthy subjects. Clin. Pharmacokinet. 60, 1171–1185 (2021).
Kiss, I. et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin. Pharmacokinet. 53, 175–183 (2014).
Granhall, C., Søndergaard, F. L., Thomsen, M. & Anderson, T. W. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin. Pharmacokinet. 57, 1571–1580 (2018).
Marbury, T. C., Flint, A., Jacobsen, J. B., Derving Karsbøl, J. & Lasseter, K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin. Pharmacokinet. 56, 1381–1390 (2017).
Thibaudeau, K. et al. Synthesis and evaluation of insulin−human serum albumin conjugates. Bioconjug. Chem. 16, 1000–1008 (2005).
Léger, R. et al. Identification of CJC-1131–albumin bioconjugate as a stable and bioactive GLP-1(7–36) analog. Bioorg. Med. Chem. Lett. 14, 4395–4398 (2004).
Baraboi, E. D. et al. Effects of albumin-conjugated PYY on food intake: the respective roles of the circumventricular organs and vagus nerve. Eur. J. Neurosci. 32, 826–839 (2010).
Ehrlich, G. K. et al. Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension. Bioconj. Chem. 24, 2015–2024 (2013).
Baker, M., Reynolds, H. M., Lumicisi, B. & Bryson, C. J. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self/Nonself 1, 314–322 (2010).
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B. & Rosenberg, A. S. Evaluating and mitigating the immunogenicity of therapeutic proteins. Trends Biotechnol. 36, 1068–1084 (2018).
Casadevall, N. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469–475 (2002).
Cantor, J. R. et al. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc. Natl Acad. Sci. USA 108, 1272–1277 (2011).
Mazor, R. et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc. Natl Acad. Sci. USA 111, 8571–8576 (2014).
Nielsen, M. et al. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput. Biol. 4, e1000107 (2008).
Vita, R. et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 43, D405–D412 (2015).
Ducret, A. et al. Assay format diversity in pre-clinical immunogenicity risk assessment: toward a possible harmonization of antigenicity assays. mAbs 14, 1993522 (2022).
Lamberth, K. et al. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Sci. Transl. Med. 9, eaag1286 (2017).
Schultz, H. S., Østergaard, S., Sidney, J., Lamberth, K. & Sette, A. The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides. PLoS ONE 13, e0197407 (2018).
Buse, J. B. et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the liraglutide effect and action in diabetes (LEAD) trials. J. Clin. Endocrinol. Metab. 96, 1695–1702 (2011).
Vora, J. et al. Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials. Diabetes Obes. Metab. 18, 716–720 (2016).
Bartley, P. C., Bogoev, M., Larsen, J. & Philotheou, A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet. Med. 25, 442–449 (2008).
Novo Nordisk A/S. [Ozempic] Summary of product characteristics. European Medicines Agency https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf (2021).
Steiner, D. et al. Half-life extension using serum albumin-binding DARPin® domains. Protein Eng. Des. Sel. 30, 583–591 (2017).
Hoogenboezem, E. N. & Duvall, C. L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 130, 73–89 (2018).
Spada, A., Emami, J., Tuszynski, J. A. & Lavasanifar, A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol. Pharm. 18, 1862–1894 (2021).
Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653–664 (2010).
Bertrand, N., Wu, J., Xu, X., Kamaly, N. & Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2–25 (2014).
Gonzaga, R. V. et al. Perspectives about self-immolative drug delivery systems. J. Pharm. Sci. 109, 3262–3281 (2020).
Sprogøe, K., Mortensen, E., Karpf, D. B. & Leff, J. A. The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency. Endocr. Connect. 6, R171–R181 (2017).
Santi, D. V., Schneider, E. L., Reid, R., Robinson, L. & Ashley, G. W. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Proc. Natl Acad. Sci. USA 109, 6211 (2012).
Alouane, A., Labruère, R., Le Saux, T., Schmidt, F. & Jullien, L. Self-immolative spacers: kinetic aspects, structure–property relationships, and applications. Angew. Chem. Int. Ed. 54, 7492–7509 (2015).
Deng, Z., Hu, J. & Liu, S. Disulfide-based self-immolative linkers and functional bioconjugates for biological applications. Macromol. Rapid Commun. 41, 1900531 (2020).
Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11, 125–140 (2012).
Goga, A. & Stoffel, M. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nat. Rev. Drug Discov. 21, 417–439 (2022).
Setten, R. L., Rossi, J. J. & Han, S. P. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 18, 421–446 (2019).
Osborn, M. F. & Khvorova, A. Improving siRNA delivery in vivo through lipid conjugation. Nucleic Acid Ther. 28, 128–136 (2018).
Brown, K. M. et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01334-x (2022).
Prakash, T. P. et al. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Res. 47, 6029–6044 (2019).
Biscans, A. et al. Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles. Mol. Ther. 29, 1382–1394 (2021).
European Medicines Agency. Levemir® CHMP assessment report. European Mediines Agency https://www.ema.europa.eu/en/documents/scientific-discussion/levemir-epar-scientific-discussion_en.pdf (2004).
European Medicines Agency. Tresiba® CHMP assessment report. European Mediines Agency https://www.ema.europa.eu/en/documents/assessment-report/tresiba-epar-public-assessment-report_en.pdf (2012).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04136067 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03965013 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02470039 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02938572 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02612844 (2022).
Shi, A. et al. Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy chinese subjects: a double-blind, phase 1, randomized controlled trial. Adv. Ther. 38, 550–561 (2021).
Granhall, C. et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin. Pharmacokinet. 58, 781–791 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04777396 (2022).
Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113–1124 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04822181 (2022).
Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A. & Kildemoes, R. J. Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clin. Pharmacokinet. 60, 1335–1348 (2021).
Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841–851 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05035095 (2022).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04667377 (2022).
Tillner, J. et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes. Metab. 21, 120–128 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02973321 (2022).
Henderson, S. J. et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 18, 1176–1190 (2016).
Ambery, P. et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 391, 2607–2618 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03235050 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03661879 (2022).
Bossart, M. et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab. 34, 59–74.e10 (2022).
US National Library of Medicine. ClinicaTtrials.gov https://clinicaltrials.gov/ct2/show/NCT04521738 (2022).
Zealand Pharma. Company announcement — No. 70/2021. GlobeNewsWire https://www.globenewswire.com/news-release/2021/11/22/2339043/0/en/Zealand-Pharma-announces-successful-outcome-of-Phase-1b-clinical-trial-with-GLP1-GLP2-dual-receptor-agonist-dapiglutide.html (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04612517 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02835235 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04969939 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03574584 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01044108 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04010786 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05016882 (2022).
Battelino, T. et al. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial. Clin. Endocrinol. 87, 350–358 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04115293 (2022).
Pedersen, K. M. et al. Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: liraglutide, insulin aspart and insulin detemir. Transl. Res. J. Lab. Clin. Med. 239, 71–84 (2022).
Albericio, F. Orthogonal protecting groups for Nα-amino and C-terminal carboxyl functions in solid-phase peptide synthesis. Pept. Sci. 55, 123–139 (2000).
Jacob, E. & Unger, R. A tale of two tails: why are terminal residues of proteins exposed. Bioinformatics 23, e225–e230 (2007).
Rosen, C. B. & Francis, M. B. Targeting the N terminus for site-selective protein modification. Nat. Chem. Biol. 13, 697–705 (2017).
Grimsley, G. R., Scholtz, J. M. & Pace, C. N. A summary of the measured pK values of the ionizable groups in folded proteins. Protein Sci. 18, 247–251 (2009).
Martos-Maldonado, M. C. et al. Selective N-terminal acylation of peptides and proteins with a Gly-His tag sequence. Nat. Commun. 9, 3307 (2018).
Rawale, D. G., Thakur, K., Adusumalli, S. R. & Rai, V. Chemical methods for selective labeling of proteins. Eur. J. Org. Chem. 2019, 6749–6763 (2019).
Huang, C. et al. Late-stage lipidation of fully elaborated tryptophan-containing peptides for improved pharmacokinetics. Tetrahedron Lett. 58, 1219–1222 (2017).
Krall, N., da Cruz, F. P., Boutureira, O. & Bernardes, G. J. L. Site-selective protein-modification chemistry for basic biology and drug development. Nat. Chem. 8, 103–113 (2016).
Kontermann, R. E. Half-life extended biotherapeutics. Expert. Opin. Biol. Ther. 16, 903–915 (2016).
Greenwald, R. B., Choe, Y. H., McGuire, J. & Conover, C. D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55, 217–250 (2003).
Jevševar, S., Kunstelj, M. & Porekar, V. G. PEGylation of therapeutic proteins. Biotechnol. J. 5, 113–128 (2010).
Paola, M., Franco, D. & Luigi, C. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr. Drug Metab. 13, 105–119 (2012).
Turecek, P. L., Bossard, M. J., Schoetens, F. & Ivens, I. A. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J. Pharm. Sci. 105, 460–475 (2016).
Solá, R. J. & Griebenow, K. Glycosylation of therapeutic proteins. BioDrugs 24, 9–21 (2010).
Fares, F. & Azzam, N. Development of long-acting recombinant glycoprotein hormones by increasing the carbohydrate content. Drug Discov. Today 24, 1017–1022 (2019).
Podust, V. N. et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J. Control. Release 240, 52–66 (2016).
Podust, V. N. et al. Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. Protein Eng. Des. Sel. 26, 743–753 (2013).
Schlapschy, M. et al. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng. Des. Sel. 26, 489–501 (2013).
Binder, U. & Skerra, A. PASylation®: a versatile technology to extend drug delivery. Curr. Opin. Colloid Interface Sci. 31, 10–17 (2017).
Kjeldsen, T. B., Hoeg-Jensen, T., Vinther, T. N., Hubalek, F. & Pettersson, I. Insulins with polar recombinant extensions. EP3303380B1 (2016).
Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132, 171–183 (2008).
Sleep, D., Cameron, J. & Evans, L. R. Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta Gen. Subj. 1830, 5526–5534 (2013).
Lee, E. S. & Youn, Y. S. Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation. J. Pharm. Invest. 46, 305–315 (2016).
Pilati, D. & Howard, K. A. Albumin-based drug designs for pharmacokinetic modulation. Expert. Opin. Drug Metab. Toxicol. 16, 783–795 (2020).
Levin, D., Golding, B., Strome, S. E. & Sauna, Z. E. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol. 33, 27–34 (2015).
Ghetie, V. et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15, 637–640 (1997).
Vaccaro, C., Zhou, J., Ober, R. J. & Ward, E. S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23, 1283–1288 (2005).
Andersen, J. T. et al. Extending serum half-life of albumin by engineering FcRn binding. J. Biol. Chem. 289, 13492–13502 (2014).
Dennis, M. S. et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277, 35035–35043 (2002).
Nguyen, A. et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng. Des. Sel. 19, 291–297 (2006).
Jonsson, A., Dogan, J., Herne, N., Abrahmsén, L. & Nygren, P.-Å. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng. Des. Sel. 21, 515–527 (2008).
Linhult, M., Binz, H. K., Uhlén, M. & Hober, S. Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin. Protein Sci. 11, 206–213 (2002).
Bao, W. et al. Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. Cardiovasc. Diabetol. 12, 148 (2013).
O’Connor-Semmes, R. L. et al. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans — PK/PD and safety. Clin. Pharm. Ther. 96, 704–712 (2014).
Walker, A. et al. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng. Des. Sel. 23, 271–278 (2010).
Read, C. et al. Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo. Basic Clin. Pharmacol. Toxicol. 126, 96–103 (2020).
Holt, L. J. et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 21, 283–288 (2008).
Zobel, K., Koehler, M. F. T., Beresini, M. H., Caris, L. D. & Combs, D. Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. Bioorg. Med. Chem. Lett. 13, 1513–1515 (2003).
Koehler, M. F. T. et al. Albumin affinity tags increase peptide half-life in vivo. Bioorg. Med. Chem. Lett. 12, 2883–2886 (2002).
Dumelin, C. E. et al. A portable albumin binder from a DNA-encoded chemical library. Angew. Chem. Int. Ed. 47, 3196–3201 (2008).
Bech, E. M. et al. Peptide half-life extension: divalent, small-molecule albumin interactions direct the systemic properties of glucagon-like peptide 1 (GLP-1) analogues. J. Med. Chem. 60, 7434–7446 (2017).
Zhou, J. et al. Phenylbutazone, a new long-acting agent that can improve the peptide pharmacokinetic based on serum albumin as a drug carrier. Chem. Biol. Drug Des. 87, 936–945 (2016).
Jonassen, I. et al. Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm. Res. 23, 49–55 (2006).
Reed, R. G. Location of long chain fatty acid-binding sites of bovine serum albumin by affinity labeling. J. Biol. Chem. 261, 15619–15624 (1986).
Hamilton, J. A., Era, S., Bhamidipati, S. P. & Reed, R. G. Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin. Proc. Natl Acad. Sci. USA 88, 2051–2054 (1991).
Simard, J. R., Zunszain, P. A., Hamilton, J. A. & Curry, S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol. 361, 336–351 (2006).
Bhattacharya, A. A., Grüne, T. & Curry, S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin1. J. Mol. Biol. 303, 721–732 (2000).
Carter, D. C. & Ho, J. X. Structure of serum albumin. Adv. Protein Chem. 45, 153–203 (1994).
Sudlow, G., Birkett, D. J. & Wade, D. N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11, 824–832 (1975).
Henninot, A., Collins, J. C. & Nuss, J. M. The current state of peptide drug discovery: back to the future? J. Med. Chem. 61, 1382–1414 (2018).
This work was funded by Novo Nordisk A/S. The authors thank F. F. Kreiner, Novo Nordisk A/S for outstanding support. They are grateful to the many present and former Novo Nordisk A/S colleagues involved in producing, purifying, quantifying, characterizing and testing some of compounds described in this Review.
All authors are employees and shareholders of Novo Nordisk A/S. T.K. is co-inventor of insulin analogues, which are described in the following patents: WO2009/115469, US Patent 9,035,020 B1 and WO2015/128403 A2. S.O. is co-inventor of peptide YY (PYY) analogues which are described in US Patent US2015/0152150 A1.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Fatty acid derivatization
The chemical coupling of a fatty acid side chain onto a peptide or a protein.
Attachment of a fatty acid to a peptide or protein. Sometimes used as an alternative term for ‘fatty acid derivatization’ in drug discovery.
Extending the half-life of a drug compound.
The chain of amino acids composing the primary structure of a peptide or protein.
The chemical element connecting the fatty acid to the spacer or to the peptide backbone in a fatty acid-derivatized peptide or protein.
The chemical element connecting the linker and the peptide backbone in a fatty acid-derivatized peptide or protein.
- Fatty monoacid
A fatty acid in the form of a long alkyl chain (12–22 carbon atoms) with one carboxylate group at the distal end.
- Fatty diacid
A fatty acid in the form of a long alkyl chain with two carboxylate groups, one at each end.
Peptides or proteins that have been modified by amino acid substitution, backbone modification and/or derivatization.
Quaternary structure in which six molecules self-associate into a structural unit.
Quaternary structure in which seven molecules self-associate into a structural unit.
- Hyperinsulinaemic, euglycaemic clamp
A method to estimate the glucose-lowering effect of an insulin at high insulin concentrations.
- Liver preferential insulin
An insulin analogue that exerts more of its action on the liver compared with subcutaneously administered human insulin.
- Self-immolative systems
Chemical structures that spontaneously undergo a degradation reaction to release the active drug substance.
Sequence-specific suppression of gene expression using modified RNA oligonucleotides.
About this article
Cite this article
Kurtzhals, P., Østergaard, S., Nishimura, E. et al. Derivatization with fatty acids in peptide and protein drug discovery. Nat Rev Drug Discov (2022). https://doi.org/10.1038/s41573-022-00529-w